https://www.pharmaradar360.com/article/sellas-life-sciences-78-events-down-two-to-go-the-trial-that-will-settle-the-bul-b35e82260c532c3fPharma Surgeen2026-07-04T15:47:22.000ZSellas Life Sciences: 78 Events Down, Two to Go — The Trial That Will Settle the Bulls vs. Bears Shttps://www.pharmaradar360.com/article/doctor-at-ou-health-leads-new-clinical-trial-for-stage-1-lung-cancer-patients-4916613f488c7a16Pharma Surgeen2026-07-04T14:35:02.000ZDoctor at OU Health leads new clinical trial for stage 1 lung cancer patientshttps://www.pharmaradar360.com/article/pune-fda-suspends-food-safety-licences-of-seven-hotels-restaurants-5e5d1dec219394d6Pharma Surgeen2026-07-04T14:25:10.000ZPune FDA Suspends Food Safety Licences of Seven Hotels, Restaurants.https://www.pharmaradar360.com/article/veraxa-biotech-vrxa-stock-price-news-analysis-2b09819439ca80fePharma Surgeen2026-07-04T14:04:16.000ZVeraxa Biotech (VRXA) Stock Price, News & Analysishttps://www.pharmaradar360.com/article/alibaba-to-pay-600m-over-allegations-of-illegal-pharmaceutical-sales-in-the-u-s-835af9ee0490a57bPharma Surgeen2026-07-04T14:00:31.000ZAlibaba to Pay $600M Over Allegations of Illegal Pharmaceutical Sales in the U.S.https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-sihuan-pharmaceutical-holdings-group-ltd-l-dd86d6aa3aa7a5cfPharma Surgeen2026-07-04T13:55:51.000ZEnterprise value to EBITDA forward of Sihuan Pharmaceutical Holdings Group Ltd. – LSX:A1C72Ghttps://www.pharmaradar360.com/article/vanguard-health-care-vs-ishares-biotech-how-do-these-etfs-stack-up-5a706bfb4567ccb7Pharma Surgeen2026-07-04T13:48:25.000ZVanguard Health Care vs. iShares Biotech: How Do These ETFs Stack Up?https://www.pharmaradar360.com/article/vanguard-health-care-vs-ishares-biotech-how-do-these-etfs-stack-up-8e32e0a9a6c803aaPharma Surgeen2026-07-04T13:35:03.000ZVanguard Health Care vs. iShares Biotech: How Do These ETFs Stack Up?https://www.pharmaradar360.com/article/tsingke-biotech-hosts-shanghai-salon-on-oligonucleotide-drugs-spotlighting-next-0bc57f1a723569e8Pharma Surgeen2026-07-04T13:00:07.000ZTsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeuticshttps://www.pharmaradar360.com/article/book-value-per-share-of-sunhawk-vision-biotech-inc-tpex-7759-41d2d74bad51a623Pharma Surgeen2026-07-04T12:31:58.000ZBook value per share of Sunhawk Vision Biotech, Inc. – TPEX:7759https://www.pharmaradar360.com/article/wall-street-thinks-this-high-flying-biotech-stock-can-soar-another-57-85cced41d01a97c2Pharma Surgeen2026-07-04T11:54:11.000ZWall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%https://www.pharmaradar360.com/article/pharmaceutical-manufacturer-relocating-corporate-headquarters-to-cincinnati-b98270dbfd02eb7ePharma Surgeen2026-07-04T11:48:50.000ZPharmaceutical manufacturer relocating corporate headquarters to Cincinnatihttps://www.pharmaradar360.com/article/know-your-company-episode-10-let-s-talk-about-boehringer-ingelheim-msci-world-in-0936d0e57c264b32Pharma Surgeen2026-07-04T11:44:11.000ZKnow Your Company Episode 10 - Let's Talk About Boehringer Ingelheim Msci World Index (QJdK4sNal9)https://www.pharmaradar360.com/article/302-995-shares-in-teva-pharmaceutical-industries-ltd-teva-purchased-by-y-interce-ecfd85b585fc22a6Pharma Surgeen2026-07-04T10:35:30.000Z302,995 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Purchased by Y Intercept Hong Kong Ltdhttps://www.pharmaradar360.com/article/is-viking-therapeutics-stock-going-to-50-here-s-what-the-bulls-and-bears-are-say-4c70f16e06fc898bPharma Surgeen2026-07-04T09:51:19.000ZIs Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Sayinghttps://www.pharmaradar360.com/article/tukaram-mundhes-crackdown-fda-suspends-7-pune-food-establishments-over-hygiene-v-c7a6481ad0df7581Pharma Surgeen2026-07-04T09:19:37.000ZTukaram Mundhes Crackdown: FDA Suspends 7 Pune Food Establishments Over Hygiene Violationshttps://www.pharmaradar360.com/article/biomarin-pharmaceutical-inc-nasdaq-bmrn-shows-strong-value-potential-with-a-7-10-7056012337c810cbPharma Surgeen2026-07-04T08:50:37.000ZBioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Ratinghttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-zhejiang-chengyi-pharmaceutical-co-ltd-class-a-sse-2da8c83dd760e670Pharma Surgeen2026-07-04T08:11:01.000ZPrice to earnings forward of Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A – SSE:603811https://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-stock-looks-overvalued-despite-upcoming-q2-earn-3ebc3cdf33948b51Pharma Surgeen2026-07-04T08:08:58.000ZWest Pharmaceutical Services (WST) Stock Looks Overvalued Despite Upcoming Q2 Earningshttps://www.pharmaradar360.com/article/price-to-sales-forward-of-haisco-pharmaceutical-group-co-ltd-class-a-szse-002653-368cfeee4f7347d7Pharma Surgeen2026-07-04T08:07:37.000ZPrice to sales forward of Haisco Pharmaceutical Group Co. Ltd. Class A – SZSE:002653https://www.pharmaradar360.com/article/resources-pharmaceutical-stocks-drive-hong-kong-stocks-higher-analyst-1a5ee5a6a063b719Pharma Surgeen2026-07-04T07:56:01.000ZResources, pharmaceutical stocks drive Hong Kong stocks higher: analysthttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-haisco-pharmaceutical-group-co-ltd-class-c14935819b4dd43aPharma Surgeen2026-07-04T07:13:24.000ZEnterprise value to revenue forward of Haisco Pharmaceutical Group Co. Ltd. Class A – SZSE:002653https://www.pharmaradar360.com/article/world-synephrine-hydrochloride-market-analysis-forecast-size-trends-and-insights-8bb7ea960517275aPharma Surgeen2026-07-04T07:11:04.000ZWorld Synephrine Hydrochloride - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/greater-bay-area-emerges-as-launchpad-for-china-s-biotech-rise-3675e582ba5d43edPharma Surgeen2026-07-04T07:09:04.000ZGreater Bay Area emerges as launchpad for China's biotech risehttps://www.pharmaradar360.com/article/vitex-inaugurates-a-250m-wonderland-manufacturing-hub-in-western-sydney-b427ed779d972026Pharma Surgeen2026-07-04T07:00:40.000ZVitex Inaugurates A$250M Wonderland Manufacturing Hub in Western Sydneyhttps://www.pharmaradar360.com/article/new-zealand-passes-landmark-mental-health-law-reform-402071d7c8a708b8Pharma Surgeen2026-07-04T06:53:32.000ZNew Zealand Passes Landmark Mental Health Law Reformhttps://www.pharmaradar360.com/article/the-partners-trial-is-running-a-clinical-experiment-that-has-never-been-done-bef-a1d07af684900c93Pharma Surgeen2026-07-04T06:42:26.000ZThe PARTNERS Trial Is Running a Clinical Experiment That Has Never Been Done Before. The World Is Watching.https://www.pharmaradar360.com/article/sarepta-announces-fda-acceptance-of-sndas-for-amondys-45-and-vyondys-53-7be94b2b54c2f9d1Pharma Surgeen2026-07-04T06:34:49.000ZSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®https://www.pharmaradar360.com/article/candel-therapeutics-an-overlooked-late-stage-biotech-with-real-potential-dd57620908978bcaPharma Surgeen2026-07-04T06:06:05.000ZCandel Therapeutics: An Overlooked Late-Stage Biotech With Real Potentialhttps://www.pharmaradar360.com/article/candel-stock-an-overlooked-late-stage-biotech-with-real-potential-nasdaq-cadl-941191180edab203Pharma Surgeen2026-07-04T06:06:05.000ZCandel Stock: An Overlooked Late-Stage Biotech With Real Potential (NASDAQ:CADL)https://www.pharmaradar360.com/article/between-two-giants-europe-s-new-oncology-chapter-takes-shape-in-paris-ed399aea4eecfc6ePharma Surgeen2026-07-04T06:02:07.000ZBetween two giants: Europe’s new oncology chapter takes shape in Parishttps://www.pharmaradar360.com/article/biotech-etf-bbc-touches-a-new-52-week-high-652d3bda4c4af155Pharma Surgeen2026-07-04T05:47:26.000ZBiotech ETF (BBC) touches a new 52-week highhttps://www.pharmaradar360.com/article/pune-fda-suspends-licences-of-10-eateries-in-hygiene-safety-crackdown-across-thr-21aa6c7e07b07171Pharma Surgeen2026-07-04T05:47:26.000ZPune FDA suspends licences of 10 eateries in hygiene & safety crackdown across three districtshttps://www.pharmaradar360.com/article/if-you-invested-1-000-in-pharmagreen-biotech-inc-phbi-85c2899557fb833dPharma Surgeen2026-07-04T05:39:50.000ZIf You Invested $1,000 in Pharmagreen Biotech Inc (PHBI)https://www.pharmaradar360.com/article/anthropic-drug-development-plan-for-ai-medicines-da7ad1a7801be055Pharma Surgeen2026-07-04T05:25:44.000ZAnthropic drug development plan for AI medicineshttps://www.pharmaradar360.com/article/fda-s-sevoflurane-probe-safety-concerns-for-venezuelan-descent-patients-04085c86c8add908Pharma Surgeen2026-07-04T04:59:57.000ZFDA's Sevoflurane Probe: Safety Concerns for Venezuelan Descent Patientshttps://www.pharmaradar360.com/article/abivax-stock-surges-on-obefazimod-safety-data-cancer-concerns-3cb2db2873196cc1Pharma Surgeen2026-07-04T03:53:55.000ZAbivax stock surges on obefazimod safety data, cancer concernshttps://www.pharmaradar360.com/article/price-to-book-forward-of-qingdao-vland-biotech-inc-class-a-sse-603739-3ce7bb1313ca1e30Pharma Surgeen2026-07-04T03:49:11.000ZPrice to book forward of Qingdao Vland Biotech INC. Class A – SSE:603739https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-raphael-pharmaceutical-inc-otc-raph-39338396e60be195Pharma Surgeen2026-07-04T03:38:58.000ZEnterprise value to EBIT forward of RAPHAEL PHARMACEUTICAL INC. – OTC:RAPHhttps://www.pharmaradar360.com/article/fda-suspends-licences-of-seven-pune-eateries-for-food-safety-violations-hindusta-861dd66e8a16e018Pharma Surgeen2026-07-04T03:21:07.000ZFDA suspends licences of seven Pune eateries for food safety violations | Hindustan Timeshttps://www.pharmaradar360.com/article/fda-cracks-down-on-energy-drinks-mumbai-news-84df7bb155deaac5Pharma Surgeen2026-07-04T03:09:36.000ZFDA cracks down on ‘energy drinks’ | Mumbai newshttps://www.pharmaradar360.com/article/ai-is-transforming-drug-discovery-here-is-the-next-trillion-dollar-biotech-oppor-e8a5a156d9d7f02ePharma Surgeen2026-07-04T02:53:29.000ZAI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunityhttps://www.pharmaradar360.com/article/etfs-investing-in-zhejiang-hisoar-pharmaceutical-co-ltd-class-a-stocks-e102683174162177Pharma Surgeen2026-07-04T02:48:36.000ZETFs Investing in Zhejiang Hisoar Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/etfs-investing-in-nanjing-hicin-pharmaceutical-co-ltd-class-a-stocks-fdd2c3118bf21095Pharma Surgeen2026-07-04T02:16:36.000ZETFs Investing in Nanjing Hicin Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/etfs-investing-in-jointown-pharmaceutical-group-co-ltd-class-a-stocks-cd730ff1f55e32aePharma Surgeen2026-07-04T01:12:56.000ZETFs Investing in Jointown Pharmaceutical Group Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/the-new-anthropic-tool-that-could-change-how-drugs-are-developed-795cf3bfa403ab0bPharma Surgeen2026-07-04T01:08:30.000ZThe New Anthropic Tool That Could Change How Drugs Are Developedhttps://www.pharmaradar360.com/article/big-pharma-enters-the-arena-next-generation-in-vivo-car-t-gains-traction-4dbb126ce0c2d655Pharma Surgeen2026-07-04T01:04:00.000ZBig Pharma Enters the Arena: Next-Generation In Vivo CAR-T Gains Tractionhttps://www.pharmaradar360.com/article/etfs-investing-in-tibet-rhodiola-pharmaceutical-holding-co-class-a-stocks-98ac33233aebd102Pharma Surgeen2026-07-04T00:46:59.000ZETFs Investing in Tibet Rhodiola Pharmaceutical Holding Co. Class A Stockshttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-aa2f6693ea3db272Pharma Surgeen2026-07-04T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-12174618bd565700Pharma Surgeen2026-07-04T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-1ad5ab45ab3ac869Pharma Surgeen2026-07-04T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-af4d7cb112be4a1fPharma Surgeen2026-07-04T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-8860ee6b7f009125Pharma Surgeen2026-07-04T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-5da8dbbd235cb6c2Pharma Surgeen2026-07-04T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-b7a0f62fe1f04b56Pharma Surgeen2026-07-04T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-0a62d2828ed2937ePharma Surgeen2026-07-04T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-4e8187def64ef73cPharma Surgeen2026-07-04T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-434501c7619b7962Pharma Surgeen2026-07-04T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-829d6f4b186326b7Pharma Surgeen2026-07-04T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-e4feafa2e1bf2207Pharma Surgeen2026-07-04T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-b44daeb9dc1dd3ebPharma Surgeen2026-07-04T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-b0fee1eab98ff54ePharma Surgeen2026-07-04T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/bridging-the-knowledge-practice-gap-in-emergency-care-at-the-primary-healthcare-e244e225b134ec5cPharma Surgeen2026-07-04T00:00:00.000ZBridging the Knowledge - practice Gap in Emergency Care at the Primary Healthcare Level: Evidence from Ahafo Ano North Municipality, Ghanahttps://www.pharmaradar360.com/article/propolis-based-solution-application-in-extraction-socket-healing-a-3d-split-mout-eb0820849921c173Pharma Surgeen2026-07-04T00:00:00.000ZPropolis-Based Solution Application in Extraction Socket Healing: A 3D Split-Mouth Clinical Pilot Studyhttps://www.pharmaradar360.com/article/protocol-for-a-modified-delphi-consensus-study-on-the-clinical-assessment-of-chi-d280ef5decfba9d6Pharma Surgeen2026-07-04T00:00:00.000ZProtocol for a Modified Delphi Consensus Study on the Clinical Assessment of Children with Suspected Olfactory Dysfunctionhttps://www.pharmaradar360.com/article/adherence-to-guideline-directed-medical-therapy-and-its-impact-on-clinical-outco-3de13ae4e8050434Pharma Surgeen2026-07-04T00:00:00.000ZAdherence to Guideline-Directed Medical Therapy and its Impact on Clinical Outcomes in Heart Failure Patients Admitted to a Teaching Hospitalhttps://www.pharmaradar360.com/article/factors-associated-with-nurses-early-warning-system-ews-scoring-accuracy-and-pat-13f5dfd00f6730bcPharma Surgeen2026-07-04T00:00:00.000ZFactors Associated with Nurses’ Early Warning System (EWS) Scoring Accuracy and Patient Clinical Outcomeshttps://www.pharmaradar360.com/article/sustainable-approach-towards-multiple-drug-resistance-exploring-the-antiswarming-f79de65a5a6393e1Pharma Surgeen2026-07-04T00:00:00.000ZSustainable Approach Towards Multiple Drug Resistance: Exploring the Antiswarming Potential of Actinobacteria in Search of Novel Metabolites.https://www.pharmaradar360.com/article/stimulants-psychoactive-plants-and-human-optimization-medical-gatekeeping-prohib-1700a17629a79acePharma Surgeen2026-07-04T00:00:00.000ZStimulants, Psychoactive Plants, and Human Optimization: Medical Gatekeeping, Prohibition, and Adult Autonomy in Drug Policyhttps://www.pharmaradar360.com/article/green-products-green-startups-and-commerce-based-innovations-as-catalysts-for-a-ef792c95dc0bdbb2Pharma Surgeen2026-07-04T00:00:00.000ZGreen Products, Green startups and Commerce based Innovations as Catalysts for a Green Economyhttps://www.pharmaradar360.com/article/molding-the-economic-mind-self-selection-indoctrination-and-student-values-in-in-01126b8f5ba35bfcPharma Surgeen2026-07-04T00:00:00.000ZMolding the Economic Mind: Self-Selection, Indoctrination, and Student Values in Indiahttps://www.pharmaradar360.com/article/hypertonicity-and-piezo1-activation-enhance-radiosensitivity-of-b16-melanoma-e1b4a5ffed42e126Pharma Surgeen2026-07-04T00:00:00.000ZHypertonicity and Piezo1 Activation Enhance Radiosensitivity of B16 Melanomahttps://www.pharmaradar360.com/article/overlapping-clinical-features-of-transfusion-related-acute-lung-injury-and-anaph-d3ca2c2ee1b07beePharma Surgeen2026-07-04T00:00:00.000ZOverlapping clinical features of transfusion-related acute lung injury and anaphylactic shock during general anesthesia: a case reporthttps://www.pharmaradar360.com/article/coenzyme-q10-as-an-adjunctive-strategy-to-reduce-paclitaxel-induced-toxicities-i-88472e00e4102034Pharma Surgeen2026-07-04T00:00:00.000ZCoenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trialhttps://www.pharmaradar360.com/article/advances-in-antibody-drug-conjugates-in-cancer-latest-updates-from-the-2026-aacr-580d0f9d4deb16b8Pharma Surgeen2026-07-04T00:00:00.000ZAdvances in antibody-drug conjugates in cancer: latest updates from the 2026 AACR annual meetinghttps://www.pharmaradar360.com/article/tailor-a-randomised-trial-to-compare-the-clinical-and-cost-effectiveness-of-a-pa-953cc71858f2210cPharma Surgeen2026-07-04T00:00:00.000ZTaILOR: a randomised trial to compare the clinical and cost-effectiveness of a patient-initiated follow-up (PIFU) strategy compared to standard care pathways in people with inflammatory arthritis: a study protocolhttps://www.pharmaradar360.com/article/brief-communication-clinical-jaundice-is-associated-with-poor-adherence-to-boost-f20ad1f92627cb7ePharma Surgeen2026-07-04T00:00:00.000ZBrief communication: clinical jaundice is associated with poor adherence to boosted atazanavir among adults in an HIV clinic in Kampala, Ugandahttps://www.pharmaradar360.com/article/efficacy-of-remote-ischemic-conditioning-on-cerebral-blood-flow-regulation-in-pa-6ef2c3a0918797b4Pharma Surgeen2026-07-04T00:00:00.000ZEfficacy of remote ischemic conditioning on cerebral blood flow regulation in patients with endovascular stenting: a randomized controlled trialhttps://www.pharmaradar360.com/article/development-and-validation-of-a-clinical-prediction-model-for-acupuncture-respon-a3ef199650862d06Pharma Surgeen2026-07-04T00:00:00.000ZDevelopment and validation of a clinical prediction model for acupuncture response in community-dwelling patients with chronic low back pain: a retrospective cohort studyhttps://www.pharmaradar360.com/article/association-between-3-d-ct-based-volumetric-fat-infiltration-of-lumbar-paraspina-55312a9c70dae686Pharma Surgeen2026-07-04T00:00:00.000ZAssociation between 3 D CT-based volumetric fat infiltration of lumbar paraspinal muscles and bone mineral density: a clinical studyhttps://www.pharmaradar360.com/article/effects-of-opioid-free-anesthesia-on-postoperative-anxiety-in-patients-undergoin-a528b50a122d4f9fPharma Surgeen2026-07-04T00:00:00.000ZEffects of opioid-free anesthesia on postoperative anxiety in patients undergoing modified radical mastectomy for breast cancer: a randomized controlled trialhttps://www.pharmaradar360.com/article/supporting-physician-well-being-and-mental-health-clinical-skill-development-eva-8dd593a08423c4c3Pharma Surgeen2026-07-04T00:00:00.000ZSupporting Physician Well-being and Mental Health Clinical Skill Development: Evaluation of Mental Health Skills Groups for Physicianshttps://www.pharmaradar360.com/article/cardiometabolic-screening-elevated-results-and-clinical-follow-up-actions-in-ma-4673fed58245ec15Pharma Surgeen2026-07-04T00:00:00.000ZCardiometabolic screening, elevated results and clinical follow-up actions in Ma-ori and non-Ma-ori with psychosis in Canterbury, Aotearoa New Zealandhttps://www.pharmaradar360.com/article/lenvatinib-versus-sorafenib-in-first-line-treatment-of-older-patients-with-unres-87adb7e96db9f96bPharma Surgeen2026-07-04T00:00:00.000ZLenvatinib Versus Sorafenib in First-Line Treatment of Older Patients With Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trialhttps://www.pharmaradar360.com/article/when-clinical-ai-hallucinates-or-appears-to-a-reflective-account-of-human-ai-dia-578ccebb826cf172Pharma Surgeen2026-07-04T00:00:00.000ZWhen Clinical AI Hallucinates or Appears To: A Reflective Account of Human-AI Diagnostic Interaction in General Practicehttps://www.pharmaradar360.com/article/how-we-study-clinical-documentation-practices-in-the-wild-a-systematic-literatur-3e94c5088a1774c3Pharma Surgeen2026-07-04T00:00:00.000ZHow We Study Clinical Documentation Practices in the Wild: A Systematic Literature Review of CHI and CSCWhttps://www.pharmaradar360.com/article/a-multidimensional-approach-to-usability-engineering-clinical-performance-and-hu-56ef7bc2579f02daPharma Surgeen2026-07-04T00:00:00.000ZA Multidimensional Approach to Usability Engineering, Clinical Performance and Human-AI Interaction in AI-Enabled Medical Deviceshttps://www.pharmaradar360.com/article/dual-coronary-sinus-lead-strategy-to-avoid-tricuspid-valve-traversal-in-biventri-d32eec151fea77ddPharma Surgeen2026-07-04T00:00:00.000ZDual Coronary Sinus Lead Strategy to Avoid Tricuspid Valve Traversal in Biventricular Pacinghttps://www.pharmaradar360.com/article/i-savor-aging-i-the-art-of-savoring-positive-emotions-in-older-adulthood-a-rando-9226514d9e47ccccPharma Surgeen2026-07-04T00:00:00.000Z<i>Savor‐Aging</i> : The Art of Savoring Positive Emotions in Older Adulthood—A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/white-phosphorus-burns-a-comprehensive-review-over-a-century-of-evidence-from-wi-7899415d9784946cPharma Surgeen2026-07-04T00:00:00.000ZWhite Phosphorus Burns: A Comprehensive Review over a Century of Evidence from “Willie Peter” to Modern Clinical Managementhttps://www.pharmaradar360.com/article/clinical-effects-and-safety-of-radiofrequency-microneedling-for-the-management-o-49eef47c814acc1fPharma Surgeen2026-07-04T00:00:00.000ZClinical Effects and Safety of Radiofrequency Microneedling for the Management of Melasma: A Retrospective Studyhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-doravirine-islatravir-for-hiv-1-a-grade-assessed-systemat-d415aa65f92771d4Pharma Surgeen2026-07-04T00:00:00.000ZEfficacy and safety of doravirine/islatravir for HIV-1: a GRADE-assessed systematic review and meta-analysis of randomized controlled trialshttps://www.pharmaradar360.com/article/assessment-of-facial-emotion-recognition-accuracy-and-reaction-time-in-patients-c39385e803d0dd9dPharma Surgeen2026-07-04T00:00:00.000ZAssessment of facial emotion recognition accuracy and reaction time in patients with social anxiety disorder diagnosed with performance-only specifierhttps://www.pharmaradar360.com/article/outcome-specific-prognostic-performance-of-pneumonia-severity-assessment-tools-f-3c2792d75514e6c1Pharma Surgeen2026-07-04T00:00:00.000ZOutcome-Specific Prognostic Performance of Pneumonia Severity Assessment Tools for Predicting a Spectrum of Multiple Clinical Eventshttps://www.pharmaradar360.com/article/cognitive-behavior-therapy-for-functional-neurological-disorder-a-systematic-rev-48934abcefe2f9dbPharma Surgeen2026-07-04T00:00:00.000ZCognitive Behavior Therapy for Functional Neurological Disorder: A Systematic Review of Therapeutic Structure and Clinical Impacthttps://www.pharmaradar360.com/article/production-optimization-of-cellulase-from-bacillus-licheniformis-and-its-applica-212538229a11df79Pharma Surgeen2026-07-04T00:00:00.000ZProduction optimization of cellulase from Bacillus licheniformis and its application in paper pulp modification and biobleachinghttps://www.pharmaradar360.com/article/deciphering-bacterial-wilt-resistance-in-eggplant-identification-of-elite-lines-78ce04c22b64ddc2Pharma Surgeen2026-07-04T00:00:00.000ZDeciphering bacterial wilt resistance in eggplant: identification of elite lines, DNA marker validation and transcriptome profilinghttps://www.pharmaradar360.com/article/antiepileptic-potential-of-salicylhydroxamic-acid-genomic-molecular-docking-and-f98239185f702d23Pharma Surgeen2026-07-04T00:00:00.000ZAntiepileptic potential of salicylhydroxamic acid: genomic, molecular docking, and functional evaluations in pentylenetetrazole-induced adult zebrafishhttps://www.pharmaradar360.com/article/a-philosophical-introduction-to-in-silico-clinical-trials-4f7fccc54964c0f8Pharma Surgeen2026-07-04T00:00:00.000ZA philosophical introduction to in-silico clinical trialshttps://www.pharmaradar360.com/article/efficacy-and-safety-of-second-line-treatments-in-alk-mutation-positive-advanced-c7ec093cb5303f6ePharma Surgeen2026-07-04T00:00:00.000ZEfficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)https://www.pharmaradar360.com/article/salivary-lipid-profile-and-malondialdehyde-levels-in-clinically-healthy-and-peri-284bb0c9100bd4f6Pharma Surgeen2026-07-04T00:00:00.000ZSalivary Lipid Profile and Malondialdehyde Levels in Clinically Healthy and Periodontally Diseased Individualshttps://www.pharmaradar360.com/article/gastrointestinal-dysfunction-in-critically-ill-patients-with-traumatic-brain-inj-4c1ed15e5e085a16Pharma Surgeen2026-07-04T00:00:00.000ZGastrointestinal Dysfunction in Critically Ill Patients With Traumatic Brain Injury: Clinical Implications and Putative Mechanisms: a Narrative Reviewhttps://www.pharmaradar360.com/article/effects-of-adding-kinesiotaping-to-conventional-physiotherapy-on-pain-function-a-4dc674c14a0bc075Pharma Surgeen2026-07-04T00:00:00.000ZEffects of adding Kinesiotaping to conventional physiotherapy on pain, function, and Kinesiophobia in knee osteoarthritis: A randomized controlled trialhttps://www.pharmaradar360.com/article/seroprevalence-of-toxoplasma-gondii-and-feline-immunodeficiency-virus-in-domesti-9f702d50b6ef5804Pharma Surgeen2026-07-04T00:00:00.000ZSeroprevalence of Toxoplasma gondii and Feline Immunodeficiency Virus in Domestic Cats and Their Associations with Clinical Signshttps://www.pharmaradar360.com/article/adaptations-in-electron-transport-chain-complexes-of-clinical-rhodococcus-equi-r-840c698114f418c8Pharma Surgeen2026-07-04T00:00:00.000ZAdaptations in electron transport chain complexes of clinical Rhodococcus equi revealed through comparative genomicshttps://www.pharmaradar360.com/article/stem-cell-based-regenerative-therapies-for-non-ischemic-cardiomyopathy-mechanist-602e4623472cda39Pharma Surgeen2026-07-04T00:00:00.000ZStem cell–based regenerative therapies for non-ischemic cardiomyopathy: mechanistic insights, clinical evidence, and future directionshttps://www.pharmaradar360.com/article/ai-enabled-clinical-decision-support-in-breast-cancer-care-a-blinded-multicenter-8f2283f7aaddc071Pharma Surgeen2026-07-04T00:00:00.000ZAI-enabled clinical decision support in breast cancer care: a blinded multicenter benchmarking study comparing medically specialized with a general-purpose systemhttps://www.pharmaradar360.com/article/intergenerational-income-mobility-and-psychotropic-drug-dispensation-in-a-1953-s-0db72f0732ee5891Pharma Surgeen2026-07-04T00:00:00.000ZIntergenerational income mobility and psychotropic drug dispensation in a 1953 Stockholm cohort: a diagonal reference model approachhttps://www.pharmaradar360.com/article/xrn2-governed-by-rna-binding-protein-ptbp3-promotes-the-invasiveness-of-esophage-62ee0ac514675703Pharma Surgeen2026-07-04T00:00:00.000ZXRN2, governed by RNA-binding protein PTBP3, promotes the invasiveness of esophageal squamous cell carcinomahttps://www.pharmaradar360.com/article/effects-of-quetiapine-on-cognitive-functioning-in-schizophrenia-evidence-for-the-121aca2300d6f423Pharma Surgeen2026-07-04T00:00:00.000ZEffects of quetiapine on cognitive functioning in schizophrenia: evidence for the remyelination hypothesis?https://www.pharmaradar360.com/article/bridging-the-gap-between-validated-cognitive-screening-and-clinical-practice-a-s-041121198c79292cPharma Surgeen2026-07-04T00:00:00.000ZBridging the Gap Between Validated Cognitive Screening and Clinical Practice: A Stylus-Driven Digital Use Case for the SAGE Testhttps://www.pharmaradar360.com/article/effects-of-trimethoprim-on-three-previously-proposed-putative-biomarkers-for-scp-e6b073a783259a91Pharma Surgeen2026-07-04T00:00:00.000ZEffects of Trimethoprim on Three Previously Proposed Putative Biomarkers for <scp>OCT2</scp> / <scp>MATE</scp> ‐Mediated Renal Drug‐Drug Interactions in Healthy Volunteershttps://www.pharmaradar360.com/article/anatomical-fidelity-in-text-to-image-generative-scp-ai-scp-a-comparative-qualita-030a22654ffabdf5Pharma Surgeen2026-07-04T00:00:00.000ZAnatomical Fidelity in Text‐to‐Image Generative <scp>AI</scp> : A Comparative Qualitative and Quantitative Evaluationhttps://www.pharmaradar360.com/article/jyong-biotech-showcases-botanical-drug-portfolio-at-bio-2026-international-conve-cb80f891cb1cdf84Pharma Surgeen2026-07-03T23:15:18.000ZJyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Conventionhttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32Pharma Surgeen2026-07-03T22:53:33.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/rigid-vinyl-films-market-forecast-points-higher-toward-2035-driven-by-pharmaceut-8de89b33c17b44afPharma Surgeen2026-07-03T22:46:06.000ZRigid Vinyl Films Market Forecast Points Higher Toward 2035, Driven by Pharmaceutical Blister Packaging Demandhttps://www.pharmaradar360.com/article/etfs-investing-in-china-resources-sanjiu-medical-pharmaceutical-co-ltd-class-a-s-46619644d398610aPharma Surgeen2026-07-03T22:39:11.000ZETFs Investing in China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/the-new-rules-of-biotech-now-available-in-hardcover-and-audiobook-695edce8bcb4ba56Pharma Surgeen2026-07-03T22:20:36.000ZThe New Rules of Biotech Now Available in Hardcover and Audiobookhttps://www.pharmaradar360.com/article/ipsen-acquires-memo-therapeutics-for-up-to-800-million-878863a839487432Pharma Surgeen2026-07-03T22:16:07.000ZIpsen acquires Memo Therapeutics for up to $800 millionhttps://www.pharmaradar360.com/article/dallas-biotech-company-and-us-to-bank-dna-of-every-endangered-species-5af8999d0a436e60Pharma Surgeen2026-07-03T21:19:02.000ZDallas biotech company and US to bank DNA of every endangered specieshttps://www.pharmaradar360.com/article/takeda-tse-4502-stock-still-looks-slightly-undervalued-overall-260dd3033624d225Pharma Surgeen2026-07-03T21:04:28.000ZTakeda (TSE:4502) Stock Still Looks Slightly Undervalued Overallhttps://www.pharmaradar360.com/article/health-headlines-from-ebola-breakthroughs-to-global-drug-deals-e1537449190efcdaPharma Surgeen2026-07-03T20:59:52.000ZHealth Headlines: From Ebola Breakthroughs to Global Drug Dealshttps://www.pharmaradar360.com/article/fda-accepts-sandoz-applications-for-generic-tirzepatide-4d9320c87a86724bPharma Surgeen2026-07-03T20:20:20.000ZFDA Accepts Sandoz Applications for Generic Tirzepatidehttps://www.pharmaradar360.com/article/is-collegium-pharmaceutical-coll-a-bargain-on-its-azstarys-deal-and-2026-guidanc-b3921fd0c98a0bd5Pharma Surgeen2026-07-03T19:27:16.000ZIs Collegium Pharmaceutical (COLL) A Bargain On Its Azstarys Deal And 2026 Guidance?https://www.pharmaradar360.com/article/pune-fda-suspends-licences-of-10-eateries-in-hygiene-safety-crackdown-across-thr-d26242045dc6d9b8Pharma Surgeen2026-07-03T19:09:00.000ZPune FDA suspends licences of 10 eateries in hygiene & safety crackdown across three districtshttps://www.pharmaradar360.com/article/giant-wheat-starch-granules-a-big-biotech-breakthrough-with-potential-benefits-f-3004c5a474a5ed30Pharma Surgeen2026-07-03T19:00:35.000ZGiant wheat starch granules - a big biotech breakthrough with potential benefits for manufacturing industrieshttps://www.pharmaradar360.com/article/new-antidepressant-prescriptions-lower-than-pre-pandemic-levels-study-finds-802bc8c0e5e0d94bPharma Surgeen2026-07-03T18:50:05.000ZNew antidepressant prescriptions lower than pre-pandemic levels, study findshttps://www.pharmaradar360.com/article/dcgi-clears-glenmark-s-phase-3-trial-of-her2-targeted-ovarian-cancer-therapy-in-d965971dd238e2dbPharma Surgeen2026-07-03T17:51:23.000ZDCGI Clears Glenmark's Phase 3 Trial of HER2-Targeted Ovarian Cancer Therapy in Indiahttps://www.pharmaradar360.com/article/us-uk-pharma-trade-deal-paints-a-costly-economic-picture-for-nhs-caa7eef372952020Pharma Surgeen2026-07-03T17:42:36.000ZUS-UK pharma trade deal paints a costly economic picture for NHShttps://www.pharmaradar360.com/article/93-republicans-support-louisiana-s-bid-to-stop-mail-order-abortions-56bbe150d4a8e2e7Pharma Surgeen2026-07-03T17:33:00.000Z93 Republicans Support Louisiana’s Bid to Stop Mail-Order Abortionshttps://www.pharmaradar360.com/article/us-biotech-loses-upc-bid-to-block-rival-s-biopsy-kit-sales-f3eb6d513d33b9d9Pharma Surgeen2026-07-03T17:29:00.000ZUS Biotech Loses UPC Bid To Block Rival's Biopsy Kit Saleshttps://www.pharmaradar360.com/article/maharashtra-bans-sale-of-high-caffeine-energy-drinks-within-500-metres-of-school-71222ef9b3466c48Pharma Surgeen2026-07-03T16:50:19.000ZMaharashtra bans sale of high-caffeine energy drinks within 500 metres of schoolshttps://www.pharmaradar360.com/article/bpgbio-moves-closer-to-phase-3-in-rare-mitochondrial-disease-dca201038fd86d55Pharma Surgeen2026-07-03T16:50:10.000ZBPGbio moves closer to Phase 3 in rare mitochondrial diseasehttps://www.pharmaradar360.com/article/maharashtra-fda-cracks-down-on-milk-adulteration-issues-stricter-norms-for-suppl-c87a25f682e22c61Pharma Surgeen2026-07-03T16:17:56.000ZMaharashtra FDA cracks down on milk adulteration, issues stricter norms for supply chainhttps://www.pharmaradar360.com/article/who-intensifies-ebola-curbing-efforts-through-drug-trial-and-diagnostic-rollout-412acf092e04a0efPharma Surgeen2026-07-03T15:47:06.000ZWHO intensifies Ebola-curbing efforts through drug trial and diagnostic rollouthttps://www.pharmaradar360.com/article/geodis-achieves-iata-ceiv-pharma-certification-in-india-fa1d29850ba420f9Pharma Surgeen2026-07-03T15:34:34.000ZGeodis achieves IATA CEIV Pharma certification in Indiahttps://www.pharmaradar360.com/article/the-mrna-1647-cmv-vaccine-from-moderna-inc-a-quiet-but-important-bet-on-long-ter-e1f53f00934d4482Pharma Surgeen2026-07-03T15:26:15.000ZThe mRNA-1647 CMV vaccine from Moderna Inc. - a quiet but important bet on long-term maternal healthhttps://www.pharmaradar360.com/article/ebola-disease-caused-by-bundibugyo-virus-democratic-republic-of-the-congo-uganda-c4d5032dd170748bPharma Surgeen2026-07-03T15:13:57.000ZEbola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Ugandahttps://www.pharmaradar360.com/article/pharmaceutical-companies-increasingly-use-celebrity-ambassadors-for-direct-to-co-1cd5410434a52317Pharma Surgeen2026-07-03T14:55:29.000ZPharmaceutical Companies Increasingly Use Celebrity Ambassadors for Direct-to-Consumer Marketinghttps://www.pharmaradar360.com/article/fda-seizes-unlabelled-ghee-namkeen-worth-over-rs-1-22-lakh-bf4d5b296eb4517cPharma Surgeen2026-07-03T14:49:58.000ZFDA Seizes Unlabelled Ghee, Namkeen Worth Over Rs 1.22 Lakhhttps://www.pharmaradar360.com/article/the-celebrity-prescription-star-power-meets-healthcare-fccc3c92df149e2ePharma Surgeen2026-07-03T14:42:31.000ZThe celebrity prescription: star power meets healthcarehttps://www.pharmaradar360.com/article/chinese-e-commerce-giant-to-cough-up-millions-over-illegal-pharmaceutical-sales-f5c099799be3f788Pharma Surgeen2026-07-03T14:16:17.000ZChinese e-commerce giant to cough up millions over illegal pharmaceutical saleshttps://www.pharmaradar360.com/article/disclosure-uk-2025-the-11th-year-of-disclosure-uk-data-with-industry-transparenc-4e954cfb9b0f2c0cPharma Surgeen2026-07-03T14:13:25.000ZDisclosure UK 2025: the 11th year of Disclosure UK data, with industry transparency continuing to growhttps://www.pharmaradar360.com/article/glenmark-advances-multi-country-phase-3-clinical-trial-of-trastuzumab-rezetecan-c3b153202d0e4e9cPharma Surgeen2026-07-03T14:04:41.000ZGlenmark Advances Multi-Country Phase 3 Clinical Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancerhttps://www.pharmaradar360.com/article/expired-food-hygiene-lapses-wagholi-and-bavdhan-restaurants-face-fda-action-in-p-36284b86c0bcde99Pharma Surgeen2026-07-03T14:00:27.000ZExpired Food, Hygiene Lapses: Wagholi and Bavdhan Restaurants Face FDA Action in Punehttps://www.pharmaradar360.com/article/pune-fda-cracks-down-on-pimple-gurav-milk-products-unit-seizes-230-kg-adulterate-6f04e38133b8b351Pharma Surgeen2026-07-03T13:51:23.000ZPune: FDA Cracks Down On Pimple Gurav Milk Products Unit, Seizes 230 KG Adulterated Gheehttps://www.pharmaradar360.com/article/fda-issues-compliance-order-for-milk-sector-in-maharashtra-warns-of-rs-10-lakh-f-92e581b9dc82af71Pharma Surgeen2026-07-03T13:49:00.000ZFDA issues compliance order for milk sector in Maharashtra; warns of Rs 10 lakh fine for violationshttps://www.pharmaradar360.com/article/vaxcyte-inc-pcvx-is-a-hidden-multibagger-stock-to-buy-now-e520d6ddb74462bfPharma Surgeen2026-07-03T13:41:42.000ZVaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Nowhttps://www.pharmaradar360.com/article/structure-therapeutics-gpcr-is-a-hidden-biotech-multibagger-stock-to-buy-now-98a4c1afac37a679Pharma Surgeen2026-07-03T13:41:31.000ZStructure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Nowhttps://www.pharmaradar360.com/article/fda-progress-could-send-this-biotech-stock-soaring-to-new-heights-eba4a8ff458b1f97Pharma Surgeen2026-07-03T13:40:34.000ZFDA Progress Could Send This Biotech Stock Soaring To New Heightshttps://www.pharmaradar360.com/article/arcutis-vs-vertex-which-pharmaceutical-maker-stock-is-a-better-buy-in-2026-56f5dce1fcdc9a72Pharma Surgeen2026-07-03T13:37:00.000ZArcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-nanjing-well-pharmaceutical-group-co-ltd-c-3217cb79dcccc2aaPharma Surgeen2026-07-03T13:22:42.000ZEnterprise value to EBITDA forward of Nanjing Well Pharmaceutical Group Co. Ltd. Class A – SSE:603351https://www.pharmaradar360.com/article/ironwood-pharmaceuticals-irwd-gains-from-strong-fiscal-q1-2026-earnings-momentum-7d900eb6fa230b85Pharma Surgeen2026-07-03T13:20:32.000Z​Ironwood Pharmaceuticals (IRWD) Gains From Strong Fiscal Q1 2026 Earnings Momentumhttps://www.pharmaradar360.com/article/gea-invests-4m-in-new-technology-center-for-scaling-biotech-and-new-food-process-8853434664544033Pharma Surgeen2026-07-03T13:18:26.000ZGEA Invests €4M in New Technology Center for Scaling Biotech and New Food Processeshttps://www.pharmaradar360.com/article/ntla-stock-surges-35-overnight-retail-mood-peaks-ahead-of-first-ever-phase-3-rea-d5beb93535a18e5ePharma Surgeen2026-07-03T13:04:43.000ZNTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapyhttps://www.pharmaradar360.com/article/laprophan-acquires-majority-stake-in-swiss-pharmaceutical-firm-rivopharm-928d1c90103a28f8Pharma Surgeen2026-07-03T13:03:56.000ZLaprophan Acquires Majority Stake in Swiss Pharmaceutical Firm Rivopharmhttps://www.pharmaradar360.com/article/air-pollution-awareness-coalition-apac-e917c85b4ebb88d0Pharma Surgeen2026-07-03T12:53:05.000ZAir Pollution Awareness Coalition (APAC)https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-meribank-biotech-co-ltd-tpex-4724-c1ecb97299acfeb2Pharma Surgeen2026-07-03T12:28:33.000ZEnterprise value to EBITDA forward of Meribank Biotech Co Ltd – TPEX:4724https://www.pharmaradar360.com/article/sihuan-pharmaceutical-holdings-group-sehk-460-following-phase-iii-trial-progress-aecdce9eecd76dc9Pharma Surgeen2026-07-03T12:23:52.000ZSihuan Pharmaceutical Holdings Group (SEHK:460) Following Phase III Trial Progress Is The Stock Too Priceyhttps://www.pharmaradar360.com/article/urinary-catheter-trays-containing-cliniclean-pericare-wipes-6e4fc641ec0aef5aPharma Surgeen2026-07-03T12:00:00.000ZUrinary Catheter Trays containing Cliniclean Pericare Wipeshttps://www.pharmaradar360.com/article/omni-tract-surgical-retractor-system-ab06fa9278057036Pharma Surgeen2026-07-03T12:00:00.000ZOmni-Tract Surgical Retractor Systemhttps://www.pharmaradar360.com/article/intramedullary-bone-saw-blade-assembly-ee53c5d0aac802cfPharma Surgeen2026-07-03T12:00:00.000ZIntramedullary Bone Saw Blade Assemblyhttps://www.pharmaradar360.com/article/hybrid-hydrophilic-microguidewire-fa63949417f7dcf4Pharma Surgeen2026-07-03T12:00:00.000ZHybrid Hydrophilic Microguidewirehttps://www.pharmaradar360.com/article/dlp-select-3d-arterial-cannula-and-dlp-elongated-one-piece-arterial-cannulae-48efec877469eb60Pharma Surgeen2026-07-03T12:00:00.000ZDLP Select 3D Arterial Cannula and DLP Elongated One Piece Arterial Cannulaehttps://www.pharmaradar360.com/article/astrazeneca-pens-1-7b-kidney-drug-discovery-pact-with-go-to-chinese-partner-cspc-04f22b7e7642ca0dPharma Surgeen2026-07-03T12:00:00.000ZAstraZeneca pens $1.7B kidney drug discovery pact with go-to Chinese partner CSPChttps://www.pharmaradar360.com/article/ebola-and-marburg-returning-workers-scheme-rws-0b1c8da0eb5eb1f7Pharma Surgeen2026-07-03T11:59:28.000ZEbola and Marburg: returning workers scheme (RWS)https://www.pharmaradar360.com/article/trust-spot-biotech-growth-soars-21-3i-group-regroups-after-may-slump-seraphim-sp-afe7835bd9c11b64Pharma Surgeen2026-07-03T11:59:21.000ZTrust Spot: Biotech Growth soars 21%; 3i Group regroups after May slump; Seraphim Space steps back from highhttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831Pharma Surgeen2026-07-03T11:57:22.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/biib-stock-ends-3-higher-why-this-strategist-picks-biogen-over-other-biotech-pee-c961ecccbe965512Pharma Surgeen2026-07-03T11:51:46.000ZBIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peershttps://www.pharmaradar360.com/article/biotech-catalyst-impending-rpn-closure-and-age-old-funding-conundrums-f9d6598cf46dc719Pharma Surgeen2026-07-03T11:49:51.000ZBiotech catalyst, impending RPN closure and age-old funding conundrumshttps://www.pharmaradar360.com/article/phosgene-market-growth-fueled-by-rising-demand-from-chemical-and-pharmaceutical-81dec8e9250b6a0cPharma Surgeen2026-07-03T11:34:24.000ZPhosgene Market Growth Fueled by Rising Demand from Chemical and Pharmaceutical Industrieshttps://www.pharmaradar360.com/article/uk-clinical-trials-performance-improves-but-remains-in-intensive-care-a298a3ad9a104fc9Pharma Surgeen2026-07-03T11:28:36.000ZUK clinical trials performance improves but remains in intensive carehttps://www.pharmaradar360.com/article/regulatory-renewal-needed-for-uk-life-sciences-ambitions-4bb95ab3c88fbca4Pharma Surgeen2026-07-03T11:28:21.000ZRegulatory renewal needed for UK life sciences ambitionshttps://www.pharmaradar360.com/article/abpi-welcomes-the-innovation-ecosystem-programme-review-46b77369fdf73babPharma Surgeen2026-07-03T11:28:06.000ZABPI welcomes the Innovation Ecosystem Programme Reviewhttps://www.pharmaradar360.com/article/abpi-welcomes-the-appointment-of-new-mhra-chair-0045e7cbe2a718acPharma Surgeen2026-07-03T11:27:54.000ZABPI welcomes the appointment of new MHRA Chairhttps://www.pharmaradar360.com/article/the-king-s-fund-calls-on-nhs-leaders-to-help-unlock-power-of-industry-partnershi-d170cb97c94f00d3Pharma Surgeen2026-07-03T11:27:42.000ZThe King’s Fund calls on NHS leaders to help unlock power of industry partnershipshttps://www.pharmaradar360.com/article/uk-missing-opportunity-to-unlock-medicines-for-severe-conditions-f7c2666360bf279cPharma Surgeen2026-07-03T11:27:28.000ZUK missing opportunity to unlock medicines for severe conditionshttps://www.pharmaradar360.com/article/abpi-response-to-sudlow-review-on-the-use-of-health-data-d153e9c792109121Pharma Surgeen2026-07-03T11:27:08.000ZABPI response to Sudlow review on the use of health datahttps://www.pharmaradar360.com/article/abpi-welcomes-the-chancellor-s-backing-of-life-sciences-in-the-budget-a21c3f1a93e42589Pharma Surgeen2026-07-03T11:26:57.000ZABPI welcomes the Chancellor’s backing of life sciences in the Budgethttps://www.pharmaradar360.com/article/fixing-nhs-needs-greater-investment-in-medicines-says-abpi-f3b5db066ae74260Pharma Surgeen2026-07-03T11:26:39.000ZFixing NHS needs greater investment in medicines, says ABPIhttps://www.pharmaradar360.com/article/mps-and-peers-urge-chancellor-to-support-the-life-sciences-in-budget-26e43c1f2dfded60Pharma Surgeen2026-07-03T11:26:28.000ZMPs and peers urge Chancellor to support the life sciences in Budgethttps://www.pharmaradar360.com/article/partnerships-build-trust-between-industry-and-healthcare-professionals-3b1cae059684032cPharma Surgeen2026-07-03T11:26:15.000ZPartnerships build trust between industry and healthcare professionalshttps://www.pharmaradar360.com/article/labour-budget-can-unlock-uk-life-science-opportunities-5a57fdc873f8915aPharma Surgeen2026-07-03T11:26:04.000ZLabour budget can unlock UK life science opportunitieshttps://www.pharmaradar360.com/article/emerging-research-points-to-nhs-and-industry-being-a-successful-partnership-for-084a390e85ec9e51Pharma Surgeen2026-07-03T11:25:50.000ZEmerging research points to NHS and industry being a successful partnership for patientshttps://www.pharmaradar360.com/article/abpi-response-to-united-nations-general-assembly-political-declaration-on-antimi-418ed7232035cd56Pharma Surgeen2026-07-03T11:25:19.000ZABPI response to United Nations General Assembly political declaration on antimicrobial resistancehttps://www.pharmaradar360.com/article/hani-friedman-bouganim-on-industrial-sovereignty-and-ai-in-pharmaceutical-manufa-b00a6099969764dbPharma Surgeen2026-07-03T11:25:09.000ZHani Friedman Bouganim on Industrial Sovereignty and AI in Pharmaceutical Manufacturinghttps://www.pharmaradar360.com/article/government-must-free-nice-to-unlock-access-to-medicines-for-severe-conditions-9af7da482b3b83f8Pharma Surgeen2026-07-03T11:25:08.000ZGovernment must free NICE to unlock access to medicines for severe conditionshttps://www.pharmaradar360.com/article/abpi-welcomes-chancellor-s-speech-at-labour-party-conference-fb622a0b234a1e7fPharma Surgeen2026-07-03T11:24:55.000ZABPI welcomes Chancellor’s speech at Labour party conferencehttps://www.pharmaradar360.com/article/2024-abpi-code-of-practice-launched-with-a-new-constitution-and-procedure-for-th-cfd9a85ec3843c7ePharma Surgeen2026-07-03T11:24:44.000Z2024 ABPI Code of Practice launched, with a new constitution and procedure for the PMCPAhttps://www.pharmaradar360.com/article/pm-says-life-sciences-is-a-key-partner-to-fixing-the-nhs-50ad590883c497bePharma Surgeen2026-07-03T11:24:31.000ZPM says life sciences is a key partner to fixing the NHShttps://www.pharmaradar360.com/article/abpi-response-to-the-darzi-review-innovation-must-be-at-the-heart-of-improvement-ae4f510da8723e75Pharma Surgeen2026-07-03T11:24:13.000ZABPI response to the Darzi Review: innovation must be at the heart of improvementhttps://www.pharmaradar360.com/article/revolution-s-ras-inhibitor-pipeline-posts-more-pancreatic-cancer-trial-wins-322c02a93f529428Pharma Surgeen2026-07-03T11:20:10.000ZRevolution’s RAS inhibitor pipeline posts more pancreatic cancer trial winshttps://www.pharmaradar360.com/article/sanofi-facility-in-waterford-receives-fda-warning-a57d264334f91496Pharma Surgeen2026-07-03T11:19:00.000ZSanofi facility in Waterford receives FDA warninghttps://www.pharmaradar360.com/article/imm-pe-calls-off-talks-to-acquire-cgbio-from-daewoong-pharmaceutical-s-owner-b614c6a1551632f1Pharma Surgeen2026-07-03T11:18:22.000ZIMM PE calls off talks to acquire CGBio from Daewoong Pharmaceutical’s ownerhttps://www.pharmaradar360.com/article/gea-invests-4m-in-german-biotech-pilot-centre-to-accelerate-food-production-scal-78e71b98c76d8538Pharma Surgeen2026-07-03T10:45:19.000ZGEA invests €4m in German biotech pilot centre to accelerate food production scale-uphttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-12-july-2026-26cc426849ce7d62Pharma Surgeen2026-07-03T10:34:32.000ZWeekly all-cause mortality surveillance: week ending 12 July 2026https://www.pharmaradar360.com/article/doj-s-marijuana-rescheduling-court-filing-sends-a-dangerous-message-3e752c93fc4c5aa6Pharma Surgeen2026-07-03T10:25:11.000ZDOJ's Marijuana Rescheduling Court Filing Sends a Dangerous Messagehttps://www.pharmaradar360.com/article/how-has-the-ukraine-shock-hit-clinical-trials-in-the-region-14d0bfb3121405c3Pharma Surgeen2026-07-03T10:17:38.000ZHow has the Ukraine shock hit clinical trials in the region?https://www.pharmaradar360.com/article/astrazeneca-and-cspc-add-renal-disease-to-rna-pact-run-c700762bf02e2614Pharma Surgeen2026-07-03T10:17:38.000ZAstraZeneca and CSPC add renal disease to RNA pact runhttps://www.pharmaradar360.com/article/kimball-steps-up-pharma-cdmo-push-with-helvoet-buy-4a53cd4528a9c1d5Pharma Surgeen2026-07-03T10:17:38.000ZKimball steps up pharma CDMO push with Helvoet buyhttps://www.pharmaradar360.com/article/pakistan-seeks-chinese-assistance-to-expand-next-cpec-phase-to-pharma-biotech-se-0969d3fb8e5d9a4dPharma Surgeen2026-07-03T10:11:25.000ZPakistan seeks Chinese assistance to expand next CPEC phase to pharma, biotech sectorshttps://www.pharmaradar360.com/article/arthur-cox-advises-on-pharmaceutical-sector-acquisition-64c3df1a5de6d934Pharma Surgeen2026-07-03T10:07:50.000ZArthur Cox advises on pharmaceutical sector acquisitionhttps://www.pharmaradar360.com/article/united-therapeutics-pays-140m-for-thymic-cell-therapy-startup-40fa14b50a64a946Pharma Surgeen2026-07-03T09:49:11.000ZUnited Therapeutics pays $140M for thymic cell therapy startuphttps://www.pharmaradar360.com/article/respiratory-biotech-celea-raises-180m-and-other-financings-26058cb0cd9e135cPharma Surgeen2026-07-03T09:34:29.000ZRespiratory biotech Celea raises $180m, and other financingshttps://www.pharmaradar360.com/article/2026-926ec18134a40c70Pharma Surgeen2026-07-03T09:28:49.000ZΓενόσημα Απριλίου 2026 _ Προτεινόμενες Τιμές προς Διαβούλευσηhttps://www.pharmaradar360.com/article/abivax-sa-abvx-nasdaq-uc-data-fuels-biotech-opportunity-7392838f094c20d5Pharma Surgeen2026-07-03T09:26:01.000ZAbivax SA (ABVX:NASDAQ) UC Data Fuels Biotech Opportunityhttps://www.pharmaradar360.com/article/satellos-bioscience-fast-track-win-fuels-dmd-hopes-c2ff12754d40043bPharma Surgeen2026-07-03T09:26:01.000ZSatellos Bioscience Fast Track Win Fuels DMD Hopeshttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-5-july-2026-c41fc7be1a6143d8Pharma Surgeen2026-07-03T09:18:19.000ZWeekly all-cause mortality surveillance: week ending 5 July 2026https://www.pharmaradar360.com/article/erkexin-275401f8d21119acPharma Surgeen2026-07-03T09:16:56.000ZERKEXIN / (ΣΙΛΔΕΝΑΦΙΛΗ, ΤΑΛΑΔΑΦΙΛΗ)https://www.pharmaradar360.com/article/mdd-class-iia-8059b94a2cab71baPharma Surgeen2026-07-03T09:03:14.000ZΑνάκληση των παρτίδων του παρακάτω πίνακα, του Ιατροτεχνολογικού προϊόντος κατηγορίας MDD Class IIa, Αρτηριακές κάνουλες ΕΟΡΑhttps://www.pharmaradar360.com/article/transthera-completes-late-stage-trial-enrollment-for-tinengotinib-cancer-drug-c3bc03f721a3f11ePharma Surgeen2026-07-03T09:02:45.000ZTransThera completes late-stage trial enrollment for Tinengotinib cancer drughttps://www.pharmaradar360.com/article/newron-charts-course-forward-for-stalled-schizophrenia-drug-95574cb1fe5ee06aPharma Surgeen2026-07-03T09:01:41.000ZNewron charts course forward for stalled schizophrenia drughttps://www.pharmaradar360.com/article/109980699-110143347-1739994-mdd-class-i-adapter-for-head-positioning-538f8473eb42a65dPharma Surgeen2026-07-03T08:57:08.000ZΑνάκληση των σειριακών αριθμών 109980699 και 110143347 του κωδικού 1739994, του Ιατροτεχνολογικού προϊόντος MDD Class I, Adapter for Head positioning (εξάρτημα προσαρμογής για τοποθέτηση κεφαλής).https://www.pharmaradar360.com/article/kissei-pharmaceutical-ordered-to-report-on-deaths-among-tavneos-users-067baa5c1435a8cdPharma Surgeen2026-07-03T08:52:07.000ZKissei Pharmaceutical Ordered to Report on Deaths among Tavneos Usershttps://www.pharmaradar360.com/article/the-rare-drug-reaction-that-can-cause-blindness-organ-damage-and-death-33cdd647f4052fb1Pharma Surgeen2026-07-03T08:46:06.000ZThe Rare Drug Reaction That Can Cause Blindness, Organ Damage, and Deathhttps://www.pharmaradar360.com/article/amgen-fights-to-keep-avacopan-on-market-amid-rising-concerns-87d4a4b0eb8eaad8Pharma Surgeen2026-07-03T08:40:51.000ZAmgen Fights to Keep Avacopan on Market Amid Rising Concernshttps://www.pharmaradar360.com/article/glenmark-launches-multi-country-phase-3-trial-of-trastuzumab-rezetecan-in-hard-t-0513579bf8e09eb5Pharma Surgeen2026-07-03T08:35:44.000ZGlenmark launches multi-country Phase 3 trial of Trastuzumab rezetecan in hard-to-treat ovarian cancerhttps://www.pharmaradar360.com/article/ecowaste-coalition-echoes-fda-b-e-a-t-reminders-on-musical-toys-907a4be6dd708b29Pharma Surgeen2026-07-03T08:24:44.000ZEcoWaste Coalition echoes FDA B.E.A.T. reminders on musical toyshttps://www.pharmaradar360.com/article/investment-bank-flags-key-novo-nordisk-metrics-as-potential-market-surprise-3d3ed25af449b283Pharma Surgeen2026-07-03T08:23:26.000ZInvestment bank flags key Novo Nordisk metrics as potential market surprisehttps://www.pharmaradar360.com/article/guidance-best-practice-in-the-labelling-and-packaging-of-medicines-d44247d0dc295239Pharma Surgeen2026-07-03T08:17:56.000ZGuidance: Best practice in the labelling and packaging of medicineshttps://www.pharmaradar360.com/article/guidance-submit-changes-to-labels-and-patient-information-leaflets-as-a-self-cer-05d8caed45ba4b2bPharma Surgeen2026-07-03T08:15:43.000ZGuidance: Submit changes to labels and Patient Information Leaflets as a self-certificationhttps://www.pharmaradar360.com/article/sky-labs-showcases-cart-bp-pro-for-potential-use-in-drug-clinical-trials-on-glob-251b586a6ed730f5Pharma Surgeen2026-07-03T08:14:00.000ZSky Labs Showcases 'CART BP pro' for Potential Use in Drug Clinical Trials on Global Stagehttps://www.pharmaradar360.com/article/startup-island-taiwan-led-delegation-secures-more-than-100-business-meetings-at-0de993c9d7bd5224Pharma Surgeen2026-07-03T08:03:00.000ZStartup Island TAIWAN-Led Delegation Secures More Than 100 Business Meetings at BIO 2026, Expanding Global Opportunities for Taiwanese Biotech Startupshttps://www.pharmaradar360.com/article/huons-starts-phase-2-trial-of-peptide-eye-drop-for-dry-eye-in-south-korea-chosun-0134213f4e15d190Pharma Surgeen2026-07-03T08:03:00.000ZHuons starts phase 2 trial of peptide eye drop for dry eye in South Korea - CHOSUNBIZhttps://www.pharmaradar360.com/article/fda-mifepristone-safety-review-advances-as-louisiana-court-deadline-nears-74536303cf31e378Pharma Surgeen2026-07-03T08:00:00.000ZFDA Mifepristone Safety Review Advances as Louisiana Court Deadline Nearshttps://www.pharmaradar360.com/article/huons-advances-phase-2-clinical-trial-of-peptide-based-dry-eye-disease-drug-huc1-65038eda657ffb6cPharma Surgeen2026-07-03T07:51:20.000ZHuons Advances Phase 2 Clinical Trial of Peptide-Based Dry Eye Disease Drug ‘HUC1-394’ with First Patient Enrollmenthttps://www.pharmaradar360.com/article/measles-mumps-or-rubella-mmr-referral-form-b8efaad36bd5f2a9Pharma Surgeen2026-07-03T07:39:33.000ZMeasles, mumps or rubella (MMR) referral formhttps://www.pharmaradar360.com/article/our-governance-e19412108cc777acPharma Surgeen2026-07-03T07:38:19.000ZOur governancehttps://www.pharmaradar360.com/article/a-new-wave-of-bridging-borders-how-us-asia-biotech-leverages-hybrid-models-to-re-d7538203073eb71aPharma Surgeen2026-07-03T07:33:28.000ZA New Wave of Bridging Borders: How US-Asia Biotech Leverages Hybrid Models to Rewrite the Rules of the Gamehttps://www.pharmaradar360.com/article/west-pharmaceutical-services-stock-10-day-winning-spree-stock-climbs-13-4c6642747cfce98fPharma Surgeen2026-07-03T07:26:52.000ZWest Pharmaceutical Services Stock 10-Day Winning Spree: Stock Climbs 13%https://www.pharmaradar360.com/article/abbvie-shares-phase-3-cll14-trial-data-for-venetoclax-combination-faa6dfd426b66212Pharma Surgeen2026-07-03T07:22:39.000ZAbbVie Shares Phase 3 CLL14 Trial Data for Venetoclax Combinationhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-stock-10-day-winning-spree-stock-climbs-13-844857d9e3ceaf45Pharma Surgeen2026-07-03T07:20:50.000ZWest Pharmaceutical Services Stock 10-Day Winning Spree: Stock Climbs 13%https://www.pharmaradar360.com/article/food-additives-and-gras-substances-a-legal-framework-d84302e88919d0c0Pharma Surgeen2026-07-03T07:19:05.000ZFood Additives and GRAS Substances: A Legal Frameworkhttps://www.pharmaradar360.com/article/register-based-study-suggests-a-slightly-increased-risk-of-meningiomas-in-women-bc26b80888780993Pharma Surgeen2026-07-03T07:14:00.000ZRegister-based study suggests a slightly increased risk of meningiomas in women using hormonal contraception containing a progestogenhttps://www.pharmaradar360.com/article/towa-pharmaceutical-co-ltd-notice-of-acquisition-of-shares-of-tanabe-pharma-fact-e730d78aef09414ePharma Surgeen2026-07-03T07:01:35.000ZTowa Pharmaceutical Co Ltd - Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvalshttps://www.pharmaradar360.com/article/brii-bio-s-enrich-study-shows-42-9-hbsag-loss-in-hepatitis-b-0302225e72b0f16dPharma Surgeen2026-07-03T06:53:51.000ZBrii Bio’s ENRICH Study Shows 42.9% HBsAg Loss in Hepatitis Bhttps://www.pharmaradar360.com/article/revolution-medicines-reports-82-response-rate-for-zoldonrasib-in-metastatic-panc-34d12a60db906fd7Pharma Surgeen2026-07-03T06:53:51.000ZRevolution Medicines Reports 82% Response Rate for Zoldonrasib in Metastatic Pancreatic Cancerhttps://www.pharmaradar360.com/article/eli-lilly-s-unapproved-weight-loss-drug-is-now-sold-at-brooklyn-corner-stores-fo-e85bee36d8bcbeeePharma Surgeen2026-07-03T06:47:13.000ZEli Lilly’s Unapproved Weight-Loss Drug Is Now Sold at Brooklyn Corner Stores for $95https://www.pharmaradar360.com/article/price-to-book-forward-of-guizhou-yibai-pharmaceutical-co-ltd-class-a-sse-600594-16e955897b843697Pharma Surgeen2026-07-03T06:26:47.000ZPrice to book forward of Guizhou Yibai Pharmaceutical Co. Ltd. Class A – SSE:600594https://www.pharmaradar360.com/article/how-one-pharmaceutical-company-charted-a-path-to-success-501311d950e10b7dPharma Surgeen2026-07-03T06:24:41.000ZHow one pharmaceutical company charted a path to successhttps://www.pharmaradar360.com/article/global-biotech-m-a-shows-signs-of-recovery-clinical-data-and-efficacy-emerge-as-dffea09c9349a19dPharma Surgeen2026-07-03T06:19:24.000ZGlobal Biotech M&A Shows Signs of Recovery, Clinical Data and Efficacy Emerge as Key Deal-Breakershttps://www.pharmaradar360.com/article/protected-cell-and-gene-therapy-patents-what-s-accelerating-what-s-lagging-behin-5c1382e0bfd233d5Pharma Surgeen2026-07-03T06:16:59.000ZProtected: Cell and gene therapy patents: What’s accelerating, what’s lagging behindhttps://www.pharmaradar360.com/article/huons-completes-merger-to-strengthen-pharma-biotech-businesses-811827b69150211cPharma Surgeen2026-07-03T04:54:58.000ZHuons completes merger to strengthen pharma, biotech businesseshttps://www.pharmaradar360.com/article/uncy-stock-on-track-for-worst-day-in-about-a-year-ahead-of-fda-decision-on-lead-781ead4101837786Pharma Surgeen2026-07-03T04:27:17.000ZUNCY Stock On Track For Worst Day In About A Year Ahead Of FDA Decision On Lead Drughttps://www.pharmaradar360.com/article/fosun-pharma-to-invest-27-5-mil-in-aribio-after-ar1001-licensing-deal-f7f455c0ca9fedc8Pharma Surgeen2026-07-03T04:20:34.000ZFosun Pharma to invest $27.5 mil. in AriBio after AR1001 licensing dealhttps://www.pharmaradar360.com/article/fda-steps-up-import-enforcement-action-on-infant-formula-cantaloupes-and-seafood-8b9118f34f88aa45Pharma Surgeen2026-07-03T04:02:12.000ZFDA steps up import enforcement action on infant formula, cantaloupes and seafoodhttps://www.pharmaradar360.com/article/emerging-therapies-for-blood-cancers-f208b8d087039c5ePharma Surgeen2026-07-03T04:00:32.000ZEmerging Therapies For Blood Cancershttps://www.pharmaradar360.com/article/3-under-the-radar-biotech-takeover-targets-for-the-next-pharma-buying-spree-d9ba590ac5c980cbPharma Surgeen2026-07-03T03:55:45.000Z3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spreehttps://www.pharmaradar360.com/article/axsm-vs-alny-which-biotech-has-the-dna-of-a-millionaire-maker-24dbdc71eab79421Pharma Surgeen2026-07-03T03:26:10.000ZAXSM vs. ALNY: Which Biotech Has the DNA of a Millionaire-Maker?https://www.pharmaradar360.com/article/newron-provides-update-following-type-a-meeting-with-the-fda-f586a646448e2f74Pharma Surgeen2026-07-03T03:10:54.000ZNewron Provides Update Following Type A Meeting With the FDAhttps://www.pharmaradar360.com/article/tcm-biotech-licenses-u101-to-u-s-subsidiary-in-deal-valued-at-750-million-4d91d71827e252bbPharma Surgeen2026-07-03T02:55:00.000ZTCM Biotech Licenses U101 to U.S. Subsidiary in Deal Valued at $750 Millionhttps://www.pharmaradar360.com/article/us-congress-probes-big-pharma-s-china-trials-pushes-fda-data-ban-chosunbiz-273c051afb89a615Pharma Surgeen2026-07-03T02:25:00.000ZUS Congress probes big pharma’s China trials, pushes FDA data ban - CHOSUNBIZhttps://www.pharmaradar360.com/article/takeda-s-new-ai-drug-discovery-deal-with-insilico-might-change-the-case-for-inve-dc8f070892023d03Pharma Surgeen2026-07-03T02:12:00.000ZTakeda’s New AI Drug Discovery Deal With Insilico Might Change The Case For Investing In Takeda Pharmaceutical (TSE:4502)https://www.pharmaradar360.com/article/biotech-focused-hedge-funds-back-talawar-s-fast-moving-spac-merger-96a110f81ffb43d0Pharma Surgeen2026-07-03T02:11:10.000ZBiotech-Focused Hedge Funds Back Talawar’s Fast Moving SPAC Mergerhttps://www.pharmaradar360.com/article/italy-pharmaceutical-lab-equipment-market-analysis-forecast-size-trends-and-insi-8c65e448d14aff1bPharma Surgeen2026-07-03T01:59:58.000ZItaly Pharmaceutical Lab Equipment - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/gpcr-stock-news-today-earnings-events-price-alerts-d695630bce6d5ce9Pharma Surgeen2026-07-03T01:34:32.000ZGPCR Stock News Today | Earnings, Events & Price Alertshttps://www.pharmaradar360.com/article/myasthenia-gravis-pipeline-2026-key-companies-moa-roa-and-clinical-trials-evalua-ab88e178e353d1b0Pharma Surgeen2026-07-03T00:30:22.000ZMyasthenia Gravis Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharma, Takedahttps://www.pharmaradar360.com/article/fosun-pharma-invests-in-aribio-to-deepen-ar1001-partnership-after-korea-deal-cho-081b3c446a42e3d2Pharma Surgeen2026-07-03T00:19:00.000ZFosun Pharma invests in Aribio to deepen AR1001 partnership after Korea deal - CHOSUNBIZhttps://www.pharmaradar360.com/article/drug-label-update-essentials-whiten-and-strengthen-23e0bb0635c763b0Pharma Surgeen2026-07-03T00:00:00.000ZDrug label update: Essentials Whiten and Strengthenhttps://www.pharmaradar360.com/article/drug-label-update-sensitive-teeth-and-gums-8c99b81c98c59652Pharma Surgeen2026-07-03T00:00:00.000ZDrug label update: Sensitive Teeth and Gumshttps://www.pharmaradar360.com/article/do-testosterone-supplements-really-work-c816e97364b1a5e2Pharma Surgeen2026-07-03T00:00:00.000ZDo Testosterone Supplements Really Work?https://www.pharmaradar360.com/article/jyong-biotech-showcases-botanical-drug-portfolio-at-bio-2026-international-conve-5f2431d757e51a38Pharma Surgeen2026-07-03T00:00:00.000ZJyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Conventionhttps://www.pharmaradar360.com/article/multi-modal-data-integration-reveals-functionally-credible-predictive-biomarkers-63a1bdcf2c9c6a49Pharma Surgeen2026-07-03T00:00:00.000ZMulti-modal data integration reveals functionally credible predictive biomarkers in ovarian cancer.https://www.pharmaradar360.com/article/neoadjuvant-tislelizumab-anti-pd-1-antibody-plus-chemotherapy-in-patients-with-a-ffc77ef34d6ace8fPharma Surgeen2026-07-03T00:00:00.000ZNeoadjuvant tislelizumab (anti-PD-1 antibody) plus chemotherapy in patients with advanced epithelial ovarian cancer: the exploratory NAIVE trial.https://www.pharmaradar360.com/article/symposium-report-stakeholders-perspectives-on-phase-1-trials-in-japanese-prior-t-bbf69573f696a6cbPharma Surgeen2026-07-03T00:00:00.000ZSymposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.https://www.pharmaradar360.com/article/recent-advances-in-physicochemical-properties-and-applications-of-schiff-bases-a-25c88552d8406389Pharma Surgeen2026-07-03T00:00:00.000ZRecent Advances in Physicochemical Properties and Applications of Schiff Bases and Heterocyclic Drug Systemshttps://www.pharmaradar360.com/article/clinical-relevant-immunosuppressive-drugs-differentially-modulate-axonal-outgrow-b260b2578f58c3ffPharma Surgeen2026-07-03T00:00:00.000ZClinical Relevant Immunosuppressive Drugs Differentially Modulate Axonal Outgrowth from Human Stem Cell Derived Neuronshttps://www.pharmaradar360.com/article/a-comprehensive-review-of-generative-ai-applications-in-drug-safety-1f556d5ed0dd115bPharma Surgeen2026-07-03T00:00:00.000ZA Comprehensive Review of Generative AI Applications in Drug Safetyhttps://www.pharmaradar360.com/article/greek-terms-in-anatomical-terminology-historical-development-and-implications-fo-a40d88e0db53d52fPharma Surgeen2026-07-03T00:00:00.000ZGreek terms in anatomical terminology: Historical development and implications for medical and pharmaceutical educationhttps://www.pharmaradar360.com/article/trial-of-labor-after-cesarean-and-vaginal-birth-after-cesarean-a-systematic-revi-d66621d545a5704aPharma Surgeen2026-07-03T00:00:00.000ZTrial of Labor After Cesarean and Vaginal Birth After Cesarean: A Systematic Review and Meta-Analysis of Maternal and Neonatal Outcomeshttps://www.pharmaradar360.com/article/patient-specific-subperiosteal-implants-for-oral-and-maxillofacial-rehabilitatio-eb34dd20ffc9214aPharma Surgeen2026-07-03T00:00:00.000ZPatient-Specific Subperiosteal Implants for Oral and Maxillofacial Rehabilitation: A Scoping Review Across Indications, from Established Full-Arch Use to Emerging Single-Tooth and Oncologic Applicationshttps://www.pharmaradar360.com/article/from-pain-relief-to-multidimensional-outcomes-a-structured-narrative-review-of-s-bb81bc97fc117b2bPharma Surgeen2026-07-03T00:00:00.000ZFrom Pain Relief to Multidimensional Outcomes: A Structured Narrative Review of Success Language in a PubMed/MEDLINE Spinal Cord Stimulation Corpushttps://www.pharmaradar360.com/article/oral-food-supplement-with-bio-activated-silicium-and-vitamins-d3-and-k2-in-the-c-3472435fad27995bPharma Surgeen2026-07-03T00:00:00.000ZOral Food Supplement with Bio-Activated Silicium and Vitamins D3 and K2 in the Conservative Management of Osteoporotic Vertebral Compression Fractureshttps://www.pharmaradar360.com/article/association-of-comprehensive-geriatric-assessment-with-knowledge-and-technique-r-b5b70ed85756ea14Pharma Surgeen2026-07-03T00:00:00.000ZAssociation of Comprehensive Geriatric Assessment with Knowledge- and Technique-Related Eye Drop Adherence Problems in Glaucoma Assessed Using the Shimane University Glaucoma Eye Drop Adherence Questionnairehttps://www.pharmaradar360.com/article/pleural-management-pathways-and-outcomes-in-haematological-malignancy-associated-977b99ca9cbccc56Pharma Surgeen2026-07-03T00:00:00.000ZPleural Management Pathways and Outcomes in Haematological Malignancy-Associated Malignant Pleural Effusionhttps://www.pharmaradar360.com/article/perspective-on-lessons-not-learned-from-coley-s-toxins-to-microbial-drug-deliver-a38848571ab3e9b2Pharma Surgeen2026-07-03T00:00:00.000ZPerspective on Lessons Not Learned: From Coley’s Toxins to Microbial Drug Delivery, Guidance for Institutional Review Boards (IRBs)https://www.pharmaradar360.com/article/maxillary-tuberosity-fractures-a-structured-narrative-review-and-clinical-decisi-549d8d22af4ac4efPharma Surgeen2026-07-03T00:00:00.000ZMaxillary Tuberosity Fractures: A Structured Narrative Review and Clinical Decision-Making Considerationshttps://www.pharmaradar360.com/article/clinical-validation-of-4k-three-dimensional-exoscope-system-in-stapedotomy-a-ret-b112105ee627fe90Pharma Surgeen2026-07-03T00:00:00.000ZClinical validation of 4K three-dimensional exoscope system in stapedotomy: a retrospective cohort studyhttps://www.pharmaradar360.com/article/clinical-significance-of-a-flattening-index-derived-from-the-flow-volume-loop-3f53551dfce6d2ddPharma Surgeen2026-07-03T00:00:00.000ZClinical significance of a flattening index derived from the flow-volume loophttps://www.pharmaradar360.com/article/clinical-implementation-of-an-automated-vmat-treatment-planning-script-for-head-a27411ea1806d8dcPharma Surgeen2026-07-03T00:00:00.000ZClinical implementation of an automated VMAT treatment planning script for head and neck cancer patients: three-year experiencehttps://www.pharmaradar360.com/article/bridging-clinical-integration-and-regulatory-compliance-in-3d-printing-a-hybrid-b86043862289075ePharma Surgeen2026-07-03T00:00:00.000ZBridging clinical integration and regulatory compliance in 3D printing: a hybrid model for university-based manufacturing of custom-made medical deviceshttps://www.pharmaradar360.com/article/epitranscriptomic-regulation-by-m6a-in-immunity-and-autoimmune-disorders-emergin-8795a253c1c888f2Pharma Surgeen2026-07-03T00:00:00.000ZEpitranscriptomic regulation by m6A in immunity and autoimmune disorders: emerging mechanisms and clinical perspectiveshttps://www.pharmaradar360.com/article/transfer-rna-expression-modification-and-derived-small-rnas-in-cancer-biology-an-d0be3039d63d8ed4Pharma Surgeen2026-07-03T00:00:00.000ZTransfer RNA expression, modification, and derived small RNAs in cancer biology and clinical potentialhttps://www.pharmaradar360.com/article/clinical-characteristics-and-outcomes-of-severe-legionella-pneumophila-pneumonia-120a4d3e4e9ad630Pharma Surgeen2026-07-03T00:00:00.000ZClinical characteristics and outcomes of severe Legionella pneumophila pneumonia diagnosed by metagenomic next-generation sequencing in children: a case series of 8 patientshttps://www.pharmaradar360.com/article/pattern-based-clinical-recognition-of-diabetes-associated-mucormycosis-an-eviden-f3680dc48af6fee5Pharma Surgeen2026-07-03T00:00:00.000ZPattern-based clinical recognition of diabetes-associated mucormycosis: an evidence mapping study integrating symptom clustering and diagnostic pathwayshttps://www.pharmaradar360.com/article/biomimetic-gradient-hydrogels-for-osteochondral-regeneration-from-multi-dimensio-9078e88e01d74b34Pharma Surgeen2026-07-03T00:00:00.000ZBiomimetic gradient hydrogels for osteochondral regeneration: from multi-dimensional design to clinical translationhttps://www.pharmaradar360.com/article/peer-review-report-for-protocol-for-a-trial-based-economic-evaluation-analysis-o-cc5b063497a1a6cePharma Surgeen2026-07-03T00:00:00.000ZPeer Review Report For: Protocol for a trial-based economic evaluation analysis of a complex digital health intervention including a computerised decision support tool: the iFraP intervention [version 2; peer review: 1 approved, 1 approved with reservations]https://www.pharmaradar360.com/article/applications-of-lasers-in-oral-medicine-14254a78865b092fPharma Surgeen2026-07-03T00:00:00.000ZApplications of Lasers in Oral Medicinehttps://www.pharmaradar360.com/article/the-role-of-chrononutrition-in-type-2-diabetes-obesity-and-night-shift-workers-b2132d5088714ae4Pharma Surgeen2026-07-03T00:00:00.000ZThe Role of Chrononutrition in Type 2 Diabetes, Obesity and Night Shift Workershttps://www.pharmaradar360.com/article/energy-efficient-communication-protocols-for-iot-devices-in-nextgeneration-wirel-d91cecaf07be3185Pharma Surgeen2026-07-03T00:00:00.000ZEnergy-Efficient Communication Protocols for IoT Devices in NextGeneration Wireless Networkshttps://www.pharmaradar360.com/article/iot-based-environmental-monitoring-enhancing-energy-efficiency-through-edge-comp-57b5af47d5f2f00cPharma Surgeen2026-07-03T00:00:00.000ZIoT-Based Environmental Monitoring: Enhancing Energy Efficiency Through Edge Computing Integrationhttps://www.pharmaradar360.com/article/preoperative-anxiety-among-patients-undergoing-elective-surgery-in-a-tertiary-ca-c7b06caa3fea5789Pharma Surgeen2026-07-03T00:00:00.000ZPreoperative Anxiety Among Patients Undergoing Elective Surgery in A Tertiary Care Centre – A Descriptive Cross-Sectional Studyhttps://www.pharmaradar360.com/article/comparative-evaluation-of-opioid-free-versus-opioid-based-anaesthesia-in-patient-92c97fd53b04dbf3Pharma Surgeen2026-07-03T00:00:00.000ZComparative Evaluation of Opioid-Free Versus Opioid-Based Anaesthesia in Patients Undergoing Spine Surgery: A Prospective Observational Studyhttps://www.pharmaradar360.com/article/occurrence-of-g-allele-at-rs1800976-of-abca1-gene-in-north-indian-population-har-a91059d5c0326467Pharma Surgeen2026-07-03T00:00:00.000ZOccurrence of G allele at rs1800976 of ABCA1 gene in North Indian population (Haryana) confers increased susceptibility to atherosclerotic complications in diabetic individualshttps://www.pharmaradar360.com/article/study-and-comparison-of-lip-print-for-sex-determination-and-permanency-over-a-ti-7d9e8270d987cab0Pharma Surgeen2026-07-03T00:00:00.000ZStudy and Comparison of Lip Print for Sex Determination and Permanency over a time period employing Three Methods: Lipstick, Latent, and Digital Photography in North Bihar Populationhttps://www.pharmaradar360.com/article/association-between-patellar-and-femoral-bone-morphology-overweight-status-and-s-24ff0dd262579014Pharma Surgeen2026-07-03T00:00:00.000ZAssociation Between Patellar and Femoral Bone Morphology, Overweight Status, and Sports Participation in Early Adolescentshttps://www.pharmaradar360.com/article/endoscopic-techniques-for-re-establishing-cerebrospinal-fluid-circulation-in-ven-8a1881eaaa48fdc3Pharma Surgeen2026-07-03T00:00:00.000ZEndoscopic Techniques for Re-establishing Cerebrospinal Fluid Circulation in Ventricular Tumorshttps://www.pharmaradar360.com/article/development-and-optimization-of-aprepitant-medicated-chocolates-by-box-behnken-e-b1619fe4a8cf5485Pharma Surgeen2026-07-03T00:00:00.000ZDEVELOPMENT AND OPTIMIZATION OF APREPITANT MEDICATED CHOCOLATES BY BOX–BEHNKEN EXPERIMENTAL DESIGNhttps://www.pharmaradar360.com/article/in-vitro-antidiabetic-activity-of-ethanolic-extract-of-parmotrema-perlatum-and-q-25e7a5aa06ea4beePharma Surgeen2026-07-03T00:00:00.000ZIN VITRO ANTIDIABETIC ACTIVITY OF ETHANOLIC EXTRACT OF PARMOTREMA PERLATUM AND QUANTITATIVE ESTIMATION OF QUERCETIN BY HPTLChttps://www.pharmaradar360.com/article/adonertinib-fhnd9041-versus-afatinib-as-first-line-treatment-for-advanced-non-sm-7fe81aa059ee053ePharma Surgeen2026-07-03T00:00:00.000ZAdonertinib (FHND9041) versus Afatinib as First-line Treatment for Advanced Non-small-cell Lung Cancer with EGFR Sensitive Mutation (FHND9041-Ⅲ-01): A Multi-centre, Open-label, Randomised Phase 3 Trial